Valneva
Valneva
VLA
EURONEXT
3.17
EUR
58.50%
About
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC).
The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 441.3K |
| Three Month Average Volume | 10.7M |
| High Low | |
| Fifty-Two Week High | 7.168 EUR |
| Fifty-Two Week Low | 2.93 EUR |
| Fifty-Two Week High Date | 10 Nov 2023 |
| Fifty-Two Week Low Date | 05 Aug 2024 |
| Price and Volume | |
| Current Price | 3.168 EUR |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -2.18% |
| Thirteen Week Relative Price Change | -21.63% |
| Twenty-Six Week Relative Price Change | 8.90% |
| Fifty-Two Week Relative Price Change | -53.04% |
| Year-to-Date Relative Price Change | -33.79% |
| Price Change | |
| One Day Price Change | -3.71% |
| Thirteen Week Price Change | -25.07% |
| Twenty-Six Week Price Change | 4.66% |
| Five Day Price Change | -8.86% |
| Fifty-Two Week Price Change | -50.79% |
| Year-to-Date Price Change | -32.88% |
| Month-to-Date Price Change | -3.71% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.92405 EUR |
| Book Value Per Share (Most Recent Quarter) | 1.19493 EUR |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.73983 EUR |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.02109 EUR |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.40753 EUR |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.10885 EUR |
| Revenue Per Share (Trailing Twelve Months) | 1.08172 EUR |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 EUR |
| Dividend Per Share (Trailing Twelve Months) | 0 EUR |
| Dividend Per Share (5 Year) | -99999.99 EUR |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.73168 EUR |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.24432 EUR |
| Normalized (Last Fiscal Year) | -0.6228 EUR |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.73168 EUR |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.23432 EUR |
| Including Extraordinary Items (Last Fiscal Year) | -0.73168 EUR |
| Including Extraordinary Items (Trailing Twelve Months) | -0.24432 EUR |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.90844 EUR |
| Cash Per Share (Most Recent Quarter) | 0.94438 EUR |
| Cash Flow Per Share (Last Fiscal Year) | -0.60484 EUR |
| Cash Flow Per Share (Trailing Twelve Months) | 0.31187 EUR |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.54163 EUR |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -36 |
| Cash Flow Revenue (Trailing Twelve Months) | -143 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -17.23% |
| Pretax Margin (Last Fiscal Year) | -64.16% |
| Pretax Margin (5 Year) | -34.52% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 34.37% |
| Gross Margin (Trailing Twelve Months) | 38.54% |
| Gross Margin (5 Year) | 35.94% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -53.40% |
| Operating Margin (Trailing Twelve Months) | -0.30% |
| Operating Margin (5 Year) | -28.45% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -65.99% |
| Net Profit Margin (Trailing Twelve Months) | -21.49% |
| Net Profit Margin (5 Year) | -34.95% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -10.14% |
| Tangible Book Value (5 Year) | 0.88% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -5.41% |
| Revenue Growth (3 Year) | 6.34% |
| Revenue Change (Trailing Twelve Months) | -55.89% |
| Revenue Per Share Growth | -4.35% |
| Revenue Growth (5 Year) | 11.69% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 35.18% |
| Total Debt (5 Year) | 29.38% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -41.67% |
| EPS Change (Trailing Twelve Months) | -1,152.28% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 4 |
| Price to Tangible Book (Most Recent Quarter) | 3 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 78.2M |
| Net Debt (Last Fiscal Year) | 82.7M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 3 |
| Price to Sales (Trailing Twelve Months) | 3 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 60 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 60 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 126 |
| Long Term Debt to Equity (Most Recent Quarter) | 113 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 2 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 13 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -217,056,000 |
| Free Cash Flow (Trailing Twelve Months) | -214,892,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -4 |
| Net Interest Coverage (Trailing Twelve Months) | -3 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 163 |
| Total Debt to Equity (Most Recent Quarter) | 126 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -18.76% |
| Return on Assets (Trailing Twelve Months) | -6.42% |
| Return on Assets (5 Year) | -15.39% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -58.29% |
| Return on Equity (Trailing Twelve Months) | -18.16% |
| Return on Equity (5 Year) | -52.02% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -31.44% |
| Return on Investment (Trailing Twelve Months) | -9.74% |
| Return on Investment (5 Year) | -25.06% |